IMP A SDB logo

Implantica AG Stock Price

OM:IMP A SDB Community·SEK 13.5b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

IMP A SDB Share Price Performance

SEK 47.50
11.00 (30.14%)
SEK 72.98
Fair Value
SEK 47.50
11.00 (30.14%)
34.9% undervalued intrinsic discount
SEK 72.98
Fair Value
Price SEK 47.50
AnalystConsensusTarget SEK 72.98

IMP A SDB Community Narratives

AnalystConsensusTarget·
Fair Value SEK 72.98 34.9% undervalued intrinsic discount

US Approval And EHealth Expansion Will Drive Long Term GERD Treatment Leadership

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
SEK 72.98
34.9% undervalued intrinsic discount
Revenue
122.41% p.a.
Profit Margin
8.07%
Future PE
1.27kx
Price in 2028
SEK 86.24

Trending Discussion

Updated Narratives

IMP A SDB logo

US Approval And EHealth Expansion Will Drive Long Term GERD Treatment Leadership

Fair Value: SEK 72.98 34.9% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with low risk.

3 Risks
1 Reward

Implantica AG Key Details

€2.0m

Revenue

€3.0m

Cost of Revenue

-€1.0m

Gross Profit

€18.7m

Other Expenses

-€19.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.07
-52.90%
-994.66%
0%
View Full Analysis

About IMP A SDB

Founded
2015
Employees
50
CEO
Peter Forsell
WebsiteView website
www.implantica.com

Implantica AG engages in the research and distribution of medical implants in Switzerland. The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a hand pumped artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for monitoring the expansion of the aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein.

Recent IMP A SDB News & Updates

Recent updates

No updates